Finn Brooks: Clara, good — you're here, because I have been sitting on this number all week and I need someone to either validate me or tell me I've lost the plot.
Clara Bennett: That is either a great sign or a terrible one. What's the number?
Finn Brooks: Twenty-eight point seven percent. Average body weight loss. Sixty-eight weeks. And — wait, this is the part — alongside a 75.8% reduction in knee pain scores. That's the TRIUMPH-4 Phase 3 trial. For retatrutide. From Eli Lilly.
Clara Bennett: That's — okay, the knee pain number is the one that actually stops me. Because that's a functional outcome, not just a scale reading.
Finn Brooks: Right — and semaglutide, Ozempic, Wegovy, whatever you want to call it, the current benchmark? Fifteen percent. So we're not talking incremental here. And then Andrew Huberman goes on the Goop Podcast — Gwyneth Paltrow's show — and calls retatrutide a 'trillion-dollar drug,' and now like, the whole thing detonates in public before the FDA has even touched it.
Clara Bennett: Huberman is a tenured professor at Stanford School of Medicine — that credibility is real. But retatrutide is still an investigational drug. It has not been approved.
Finn Brooks: Okay but — no, I want to sit with the numbers first, because I think the reflex to pump the brakes on Huberman actually obscures how good this data genuinely is. Is the hype wrong, or is it just early?
Clara Bennett: The data is real — I'm not disputing that. But the comparison you just made, 28.7 versus 15, that arithmetic is doing something it shouldn't be doing. Those are different trials, different durations, different patient populations. You can't just subtract the percentages and call it a margin.
Finn Brooks: Wait — like, meaningfully different populations, or just technically different?
Clara Bennett: Meaningfully. TRIUMPH-4 specifically enrolled people with obesity AND knee osteoarthritis — that's a population where movement is already compromised. The semaglutide trials weren't built that way. So imagine two cars — one on a flat highway, one climbing a hill — and someone hands you both speedometers and says, see, this one's faster. You can't read it that way. The instruments aren't measuring the same conditions. And there's a whole middle vehicle nobody's accounting for — tirzepatide, which is already approved as Mounjaro and Zepbound. Dual GLP-1 and GIP receptor agonist. That's the actual intermediate step between semaglutide and retatrutide, and it never enters this conversation.
Finn Brooks: Okay that — yeah, tirzepatide just completely falls out of the narrative whenever Huberman says 'trillion-dollar drug,' doesn't it.
Clara Bennett: It does. And now the harder fact — the gray market piece. Compounding pharmacies legally produced semaglutide during its shortage, that's established. But retatrutide? Under current federal law, compounding pharmacies cannot legally touch it. It's not a gray area. So the 120-plus websites selling it right now are not selling compounded retatrutide in any regulated sense — they're selling unverified product the FDA has specifically flagged. That's not 'early access.' That's something else entirely.
Finn Brooks: And that's — wait, that's before we even get to how Huberman's Stanford affiliation made 'investigational' sound like 'available' to a Goop audience. That part genuinely makes this worse.
Clara Bennett: That's exactly the mechanism worth naming. Because Huberman's credibility didn't transfer generically — it transferred specifically. The Huberman Lab podcast built an audience that trusts him on neuroscience and physiology. Real, earned trust. But the Goop Podcast sits inside a wellness culture that has — and I'm being precise here — a documented history of promoting unverified health claims. So when those two things collide, the audience doesn't parse 'investigational Phase 3.' They hear a Stanford neuroscientist confirming something Goop already primed them to want.
Finn Brooks: Wait — Public Citizen actually flagged this specifically? Like, the influencer-to-gray-market pipeline?
Clara Bennett: They flagged the enforcement gap, yes. The FDA has no clear authority over influencer promotion of unapproved drugs. That's the structural hole. And into that hole walk 120-plus websites.
Finn Brooks: Okay but — and I want to give Huberman something here, because I think the reflex to blame him flattens this — the TRIUMPH-4 data is real. He wasn't inventing efficacy. So is the problem that he spoke, or is it the venue?
Clara Bennett: The venue plus one specific claim. Picture someone — late fifties, bad knees, sees the Goop clip on a Thursday evening. What she hears is that this drug also crushed knee pain. That's the hook. And the muscle-preservation angle is even more compelling to that person — but that claim is built entirely on how the glucagon receptor component theoretically boosts fat oxidation. The TRIUMPH-4 results report total weight loss. Not lean mass versus fat mass. That breakdown does not exist in any published Phase 3 data. So Goop's audience received a pharmacological hypothesis as a proven biohacking outcome. That's the actual harm.
Finn Brooks: So the most viral part of the story — preserve muscle, burn fat — is mechanistically plausible but clinically unconfirmed. And TRANSCEND-T2D-1 and the other Phase 3s aren't even done until 2026.
Clara Bennett: Seven more Phase 3 trials, including TRANSCEND-T2D-1, still running. The data isn't finished. And the woman with the bad knees doesn't know that part. That's where the excitement being rational — and it is rational — doesn't make the information transfer safe.
Finn Brooks: I mean — fine. 'Trillion-dollar drug' on a wellness podcast before FDA approval is maybe, I don't know, slightly ahead of schedule as a characterization.
Clara Bennett: The real risk isn't that retatrutide fails. It's that it succeeds — because then every gray-market purchase between now and 2026 looks like early wisdom, and the next unapproved drug arrives to find an audience that already knows exactly how to buy it.
Finn Brooks: Yeah. That's the part that actually keeps me up a little.
Clara Bennett: Good conversation. Genuinely.
